FAP - fibroblast activation protein alpha Gene
Species: Felis catus
Gene Type: protein coding
Gene ID: 101098974
FAP Products (2)
| mRNA | Protein | Name |
|---|---|---|
| XM_011285347.3 | XP_011283649.1 | prolyl endopeptidase FAP isoform X1 |
| XM_019838169.1 | XP_019693728.1 | prolyl endopeptidase FAP isoform X2 |
| Protein Preferred Names | Protein Names | |
|---|---|---|
|
prolyl endopeptidase FAP |
|
Related Agents
- Clinical Phase
- Pre-clinical Phase
Clinical Phase
Bioactive Molecules
(4)
| Cat. No. | Product Name |
Effect
|
Purity |
Phase |
|---|---|---|---|---|
| HY-P3392A | Zilganersen sodium | Inhibitor | 91.43% | Phase 3 |
| HY-P3392 | Zilganersen | 91.43% | Phase 3 | |
| HY-137331 | FAPI-46 | 99.02% | Phase 2 | |
| HY-172317 | AZD2389 | Inhibitor | 99.65% | Phase 2 |
Inhibitory Antibodies
(1)
| Cat. No. | Product Name |
Effect
|
Purity |
Phase |
|---|---|---|---|---|
| HY-P99269 | Sibrotuzumab | 99.05% | Phase 2 |
Pre-clinical Phase
Bioactive Molecules
(75)
| Cat. No. | Product Name |
Effect
|
Purity |
Rare Diseases
|
|---|---|---|---|---|
| HY-147057 | Rofapitide tetraxetan | 99.54% | Unkown | |
| HY-128643 | FAPI-4 | 99.47% | Unkown | |
| HY-100684 | UAMC-1110 | Inhibitor | 99.51% | Unkown |
| HY-101801 | Ac-Gly-BoroPro | 98.0% | Unkown | |
| HY-145983 | Suc-Gly-Pro-AMC | 99.85% | Unkown | |
| HY-147173 | FAPI-74 | 99.84% | Unkown | |
| HY-153552A | NH2-UAMC1110 TFA | Inhibitor | 99.98% | Unkown |
| HY-145938 | OncoFAP | 99.77% | Unkown | |
| HY-P10944 | Unlabeled FXX489 | Ligand | 98.52% | Unkown |
| HY-160289 | ARI-3144 | Substrate | 99.72% | Unkown |
| HY-P10131 | 3BP-3940 | 99.49% | Unkown | |
| HY-164725 | FAPI-mFS | Inhibitor | 98.71% | Unkown |
| HY-164316 | FT-FAPI-12_9 | 99.07% | Unkown | |
| HY-125366 | ARI-3099 | Inhibitor | 99.95% | Unkown |
| HY-47979 | FAP-IN-2 | Inhibitor | 99.93% | Unkown |
| HY-136641 | NOTA-FAPI | Inhibitor | 99.66% | Unkown |
| HY-P3441A | 3BP-4089 TFA | Inhibitor | 99.27% | Unkown |
| HY-D2363 | DOTA.SA.FAPi TFA | Inhibitor | 99.26% | Unkown |
| HY-P10945 | FAP targeting peptide for FXX489 | 99.49% | Unkown | |
| HY-139401 | FAPI-34 | Ligand | 98.04% | Unkown |
| HY-161074 | PNT6555 | 96.55% | Unkown | |
| HY-164364A | DOTAGA.(SA.FAPi)2 TFA | Inhibitor | 97.51% | Unkown |
| HY-175350 | OncoFAP-GlyPro-MMAE | Ligand | 99.71% | Unkown |
| HY-177435 | FAPI-800CW | Inhibitor | 99.40% | Unkown |
| HY-47979A | FAP-IN-2 TFA | Inhibitor | 99.92% | Unkown |
| HY-153552 | NH2-UAMC1110 | Inhibitor | 99.86% | Unkown |
| HY-P10945B | Cys-FAP targeting peptide for FXX489 TFA | 95.77% | Unkown | |
| HY-175613 | DOTA-ALB-02 | Ligand | 99.71% | Unkown |
| HY-173374 | DOTAGA-FAP-2286-ALB | Inhibitor | 99.29% | Unkown |
| HY-147057A | Rofapitide tetraxetan acetate | / | Unkown | |
| HY-164567 | SID 125240931 | 98.75% | Unkown | |
| HY-183513 | L-Ala-BPA | Substrate | / | Unkown |
| HY-128642 | FAPI-2 | 98.94% | Unkown | |
| HY-164316A | FT-FAPI-12_9 TFA | 99.48% | Unkown | |
| HY-159771 | FAP6-19 | Ligand | / | Unkown |
| HY-D2281 | FAP Ligand 2 | / | Unkown | |
| HY-159768A | DOTAGA.Glu.(FAPi)2 | Ligand | / | Unkown |
| HY-177083 | Faridoxorubicin | Substrate | / | Unkown |
| HY-175612 | DOTA-ALB-01 | Ligand | / | Unkown |
| HY-172137 | FAPI-FUSCC-07 | Ligand | / | Unkown |
| HY-175685 | FAP-IN-7 | Inhibitor | / | Unkown |
| HY-176958 | OncoFAP-EN-DOTAGA | Inhibitor | / | Unkown |
| HY-164364B | DOTAGA.(SA.FAPi)2 analogue TFA | Inhibitor | 99.38% | Unkown |
| HY-P3392C | Zilganersen sodium scrambled negative control | Inhibitor | / | Unkown |
| HY-146182 | FSDD3I | / | Unkown | |
| HY-177459 | DOTA-2P(FAPI)2 | Inhibitor | / | Unkown |
| HY-182272 | FAP-IN-9 | Inhibitor | / | Unkown |
| HY-175330 | FAP-IN-6 | Inhibitor | / | Unkown |
| HY-186190 | I-FAPI-04 prodrug-1 | Inhibitor | / | Unkown |
| HY-146181 | FSDD1I | / | Unkown | |
| HY-P10945A | Cys-FAP targeting peptide for FXX489 | / | Unkown | |
| HY-182250 | BR103354 | Inhibitor | / | Unkown |
| HY-173319 | FAP-IN-5 | Inhibitor | / | Unkown |
| HY-178981 | FAP-IN-8 | Inhibitor | / | Unkown |
| HY-128642A | FAPI-2 TFA | 98.05% | Unkown | |
| HY-P3441 | 3BP-4089 | Inhibitor | 99.27% | Unkown |
| HY-158326 | FAP-IN-4 | Inhibitor | / | Unkown |
| HY-159934 | QI-18 | Inhibitor | / | Unkown |
| HY-103323 | Fas C-Terminal Tripeptide | Inhibitor | / | Unkown |
| HY-148361 | Fluorogen binding modulator-1 | / | Unkown | |
| HY-175353 | TriOncoFAP-GlyPro-MMAE | / | Unkown | |
| HY-146180 | FSDD0I | / | Unkown | |
| HY-175322 | FAPI-P8PN | Inhibitor | / | Unkown |
| HY-182434 | CL 118326 | Antagonist | / | Unkown |
| HY-183796 | GFAP/NF-κB/APOE/NLRP3-IN-1 | Inhibitor | / | Unkown |
| HY-170779 | DOTA-NI-FAPI-04 | Inhibitor | / | Unkown |
| HY-149860 | FAP-IN-1 | Inhibitor | / | Unkown |
| HY-P11602 | DOTA-C1-FAP-2286 | / | Unkown | |
| HY-174421 | FAPI-JNU | Ligand | / | Unkown |
| HY-161262 | SB03178 | Inhibitor | / | Unkown |
| HY-P11599 | NOTA-SP2A-FAPT | Ligand | / | Unkown |
| HY-181494 | FAPI-X5 | Inhibitor | / | Unkown |
| HY-181580 | FAP Ligand 3 | Ligand | / | Unkown |
| HY-163079 | AlF-PD-FAPI | / | Unkown | |
| HY-W668749 | 3BP-3580 | Inhibitor | / | Unkown |
Bioactive MoleculesInhibitory Antibodies
(2)
| Cat. No. | Product Name |
Effect
|
Purity |
Rare Diseases
|
|---|---|---|---|---|
| HY-P990245 | Anti-Mouse FAP Antibody (73.3) | Inhibitor | 95.00% | Unkown |
| HY-P991995 | OMTX005 | Inhibitor | 98.44% | Unkown |